Journal
BIOMOLECULES
Volume 11, Issue 4, Pages -Publisher
MDPI
DOI: 10.3390/biom11040607
Keywords
COVID-19; SARS-CoV-2 M-pro; protease inhibitors; coronavirus; peptidomimetics; remdesivir
Categories
Funding
- [FFABR_PA_MICALE_NICOLA_ ATENEO_2020_II_EDIZIONE]
Ask authors/readers for more resources
The uncontrolled spread of COVID-19 caused by SARS-CoV-2 in 2020-2021 had devastating impacts on health, economy, and daily life globally. Despite approved vaccines, their long-term efficacy and safety are debated, prompting the search for new target-based drugs. Strategies targeting the coronavirus's main protease, M-pro, show promise for anti-coronavirus drug development.
The uncontrolled spread of the COVID-19 pandemic caused by the new coronavirus SARS-CoV-2 during 2020-2021 is one of the most devastating events in the history, with remarkable impacts on the health, economic systems, and habits of the entire world population. While some effective vaccines are nowadays approved and extensively administered, the long-term efficacy and safety of this line of intervention is constantly under debate as coronaviruses rapidly mutate and several SARS-CoV-2 variants have been already identified worldwide. Then, the WHO's main recommendations to prevent severe clinical complications by COVID-19 are still essentially based on social distancing and limitation of human interactions, therefore the identification of new target-based drugs became a priority. Several strategies have been proposed to counteract such viral infection, including the repurposing of FDA already approved for the treatment of HIV, HCV, and EBOLA, inter alia. Among the evaluated compounds, inhibitors of the main protease of the coronavirus (M-pro) are becoming more and more promising candidates. M-pro holds a pivotal role during the onset of the infection and its function is intimately related with the beginning of viral replication. The interruption of its catalytic activity could represent a relevant strategy for the development of anti-coronavirus drugs. SARS-CoV-2 M-pro is a peculiar cysteine protease of the coronavirus family, responsible for the replication and infectivity of the parasite. This review offers a detailed analysis of the repurposed drugs and the newly synthesized molecules developed to date for the treatment of COVID-19 which share the common feature of targeting SARS-CoV-2 M-pro, as well as a brief overview of the main enzymatic and cell-based assays to efficaciously screen such compounds.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available